The U.S. Food and Drug Administration (FDA) has approved Evorpacept to treat head and neck squamous cell carcinoma (HNSCC), and HER2-positive gastric or gastroesophageal junction malignancies. Here, ERBB2 is linked to head and neck squamous cell carcinoma.